MGM Resorts International vs Zoetis Inc — how do they compare? MGM Resorts International trades at $40.18 (market cap $10.25B), while Zoetis Inc trades at $73.65 (market cap $30.40B). The key difference: Zoetis Inc is far larger — about 3× MGM Resorts International's market cap, and Zoetis Inc pays the higher dividend (2.88%). Which is the better fit depends on your goals.
| MGM | ZTS | |
|---|---|---|
Market Cap | $10.25B | $30.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $50.69 | $150.61 |
52-Week Low | $30.72 | $71.91 |
Enterprise Value | $37.55B | $37.96B |
Dividend Yield | 0.03% | 2.88% |
Signals from Pluang's Aura AI — not financial advice
MGM Resorts International (MGM) trades at $40.74, down 1.16% on the day, with a bearish technical signal but bullish oscillators like RSI indicating potential oversold conditions. Revenue grew to $17.54B in 2025, though net income margin compressed to 2.4%. Recent news includes a $48.30 per share acquisition offer under investigation and BetMGM's football season enhancements, reflecting mixed operational and strategic developments.
The stock presents a valuation opportunity with a low P/S of 0.61 and strong analyst consensus price target of $51.61, but faces risks from declining profitability, high debt, and regulatory scrutiny. Upside hinges on execution in digital and international segments, while investor sentiment is cautious amid earnings volatility and acquisition uncertainty.
Zoetis (ZTS) trades at $73.60, down 2.92% amid bearish technical signals and mixed earnings. The stock faces pressure from weakening U.S. companion animal sales and competitive headwinds, though profitability remains strong with 71.67% gross margins and 27.69% net income margin. Recent Q2 2026 earnings beat estimates but revenue missed, prompting a guidance cut. Analyst consensus is divided with 45% Buy ratings and a $93.40 price target, suggesting 27% upside from current levels.
The outlook balances valuation appeal (P/E of 12) against near-term operational challenges. Investment opportunity lies in market dominance and robust cash flow generation, while risks include sustained pet health demand softness and competitive pricing pressure. The stock trades near support at $73, with institutional sentiment mixed amid recent portfolio adjustments.
Trailing returns across standard periods
Latest headlines on both assets
MGM Resorts is the largest resort operator on the Las Vegas Strip with 35,000 guest rooms and suites, representing about one fourth of all units in the market. The company's Vegas properties include MGM Grand, Mandalay Bay, Cosmopolitan, Luxor, New York-New York, and CityCenter. The Strip contributed approximately 49% of total EBITDAR in the prepandemic year of 2019. MGM also owns U.S. regional assets, which represented 29% of 2019 EBITDAR. we estimate MGM's U.S. sports and iGaming operations are currently a mid-single-digit percentage of its total revenue. The company also operates the 56%-owned MGM Macau casinos with a new property that opened on the Cotai Strip in early 2018. Further, we estimate MGM will open a resort in Japan in 2027.
Read more on MGM →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →